Cytosorbents Corp
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $9.60M | $-0.07 | $-0.05 |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $8.90M | $-0.08 | $-0.05 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | During market hours | $9.20M | $0.09 | $0.07 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $9.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $8.70M | $-0.02 | $-0.06 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $9.40M | $-0.04 | $-0.08 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | $9.90M | $-0.08 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | – | – | – |
Company guidance
Outlook given with results on Mar 4, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| product gross margin | Fourth quarter | 70% | New |
| product revenue (excluding grant income) | Fourth quarter | $9.00M to $9.20M | New |
| product revenue (excluding grant income) | Full-year | $35.40M to $35.60M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Cytosorbents filed with the SEC
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CytoSorbents Corporation Nasdaq: CTSO Q2 2026 Earnings Conference Call August 6, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Results of operations · EX-99.1 to Form 8-K
| 1 1 NASDAQ: CTSO Life Sciences Forum June 24, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED MAY 13, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED MARCH 25, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
CytoSorbents Provides DrugSorb-ATR Regulatory Update
Regulation FD disclosure · Other events · EX-99 to Form 8-K
CytoSorbents Updates U.S. FDA Regulatory Status
Other events · EX-99.1 to Form 8-K
CytoSorbents Leads a New Era in Sepsis Treatment
Other events · EX-99.1 to Form 8-K
Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
Other events · EX-99.1 to Form 8-K
CytoSorbents Files Appeal with U.S. FDA for
Other events · EX-99.1 to Form 8-K
CytoSorbents Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
CytoSorbents Provides Regulatory Update for
Other events · EX-99.1 to Form 8-K
CytoSorbents Appoints Melanie Grossman, CPA
Regulation FD disclosure · EX-99.1 to Form 8-K
CytoSorbents Appoints Thomas Shannon as Vice
Regulation FD disclosure · EX-99.1 to Form 8-K
CytoSorbents Extends Expiration Date of Outstanding
Other events · EX-99.1 to Form 8-K
CytoSorbents Reports Fourth Quarter and Full
Results of operations · EX-99.1 to Form 8-K
CytoSorbents Reschedules Earnings Release to
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CytoSorbents Postpones Earnings Release to
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
Regulation FD disclosure · EX-99.1 to Form 8-K
Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CytoSorbents Expands Global Footprint with Opening
Other events · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2024 Product Revenue
Results of operations · EX-99.1 to Form 8-K
To Participate, Eligible Stockholders Should
Regulation FD disclosure · EX-99.1 to Form 8-K
THE TERMS AND CONDITIONS OF THE OFFERING ARE SET
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
THE TERMS AND CONDITIONS OF THE OFFERING ARE SET FORTH IN THE COMPANY’S
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TO STOCKHOLDERS AND CERTAIN ELIGIBLE WARRANTHOLDERS
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Reports Third Quarter 2024 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
Submits DrugSorb™-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on
Results of operations · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
CytoSorbents Announces Compliance with Nasdaq
Other events · EX-99.1 to Form 8-K
CytoSorbents Secures $20 Million Credit Facility
Material agreement · Other events · EX-99.1 to Form 8-K
CytoSorbents Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Groundbreaking Randomized Controlled Trial Reports
Listing notice · Other events · EX-99.1 to Form 8-K
CytoSorbents Provides Update on the STAR-T Trial
Other events · EX-99.1 to Form 8-K
CytoSorbents Announces Closing of $10.3 Million
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
at EACTS 2023: Focus on Antithrombotic Removal including the 2 nd Analysis of the International STAR Registry
Other events · EX-99.1 to Form 8-K